Abstract Library

#1845 Mismatch Repair (MMR) Protein Expression is Uncommon in Poorly Differentiated Neuroendocrine Carcinoma

Introduction: Microsatellite instability (MSI) has been reported to occur in a significant proportion of neuroendocrine carcinoma (NEC) and mixed adenoneuroendocrine carcinomas (MANEC) (11 out of 89 cases, Sahnane et al, ERC 2015). It might be predictive of response to immunotherapy.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Hadoux J

Authors: Hadoux J, Malka D, Berdeloux A, Planchard D, Boige V,

Keywords: Neuroendocrine carcinoma, mismatch repair, microsatellite instability,

#1537 Antitumor Efficacy of Temozolomide in Patients with Metastatic Pulmonary Carcinoids

Introduction: Temodal (TMZ) is an oral alternative to dacarbazine.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Bello Roufai D, Planchard D, Walter T, Berdelou A, Guigay J,

Keywords: pulmonary carcinoids, temozolomide, safety,

#1244 Everolimus in Progressive Metastatic Pancreatic Neuroendocrine Tumors: Analyses of Median Progression Free Survival and Safety in the Real Life Setting

Introduction: Everolimus is an oral inhibitor of mammalian target of rapamycin(mTOR) with antitumor activity in patients(pts) with pancreatic neuroendocrine tumor(pNET)s

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Del Prete M

Authors: Del Prete M, Malka L, Borget I, Berdelou A, Boige V,

Keywords: Pancreatic Neuroendocrine Tumor, Everolimus, Safety,

#831 Overall Survival (OS) as a Function of the Number of Therapeutic Lines in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors (WDpNET)

Introduction: At least 9 therapeutic options are now available for unresectable WDpNET patients. Whether all lines can be administrated before tumor or toxic-related deaths is currently unknown.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Berdelou A, Malka D, Leboulleux S, Boige V, Chougnet C,

Keywords: pNets,